Zura Bio Limited
ZURA | NASDAQ
$4.54
+$0.04 (+0.89%)
Sep 22, 2026, 2:42 PM ET · Market open
Company Profile
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
Key Executives
| Name | Position |
|---|---|
| Sandeep Chidambar Kulkarni | Co-Founder, CEO & Director |
| Gary Whale | Chief Technology Officer |
| Kimberly Ann Davis | Chief Operating Officer, Chief Legal Officer & Corporate Secretary |
| Kiran Nistala MBBS | Chief Medical Officer & Head of Development |
| Marlyn Mathew | VP of Finance & Accounting and Principal Financial & Accounting Officer |
| Muzammil Mustufa | Chief Business Officer |
| Theresa Lowry | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 17, 2026 | 8-K | Current Report |
| Aug 11, 2026 | 8-K | Current Report |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Jul 01, 2026 | 8-K | Current Report |
| Jun 22, 2026 | 3 | Filing |
| Jun 22, 2026 | 4 | Filing |
| Jun 22, 2026 | 4 | Filing |
| Jun 22, 2026 | 4 | Filing |
| Jun 22, 2026 | 4 | Filing |
| Jun 22, 2026 | 4 | Filing |
Zura Bio Limited
| Country | United States |
| IPO Date | Mar 20, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 40 |
| CEO | Sandeep C. Kulkarni |
Contact Details
1489 W. Warm Springs Road Henderson,
Nevada 89014 United States
Stock Details
| Ticker Symbol | ZURA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001855644 |
| CUSIP Number | G9TY5A101 |
| ISIN Number | KYG9TY5A1016 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove ZURA